Abstract
4/2021
vol. 27
Case report
Ultrafast acting insulin analog – a new way to prevent postprandial hyperglycemia and improve quality of life in type 1 diabetes patients – case reports
- Department of Pediatrics, Oncology, Haematology and Diabetology, Medical University of Lodz, Poland
Pediatr Endocrinol Diabetes Metab 2021; 27 (4): 305–310
Online publish date: 2021/12/30
The aim of modern insulin therapy used in the treatment of type 1 diabetes mellitus is to mimic the physiological secretion of insulin in order to ensure stable normoglycemia while maintaining the greatest possible comfort of life for diabetic patients. New ultra-fast insulin analogs that can be administered immediately before a meal contribute to the improvement of postprandial glycemia and the quality of life of patients. We presented two cases illustrating the effectiveness and safety of the use of an ultra-fast-acting insulin analog in the treatment of postprandial hyperglycemia in children with type 1 diabetes.
Keywords
type 1 diabetes mellitus, postprandial hyperglycemia, time in range, ultrafast-acting analog of insulin, children
Integrated with
